PeptideStack
5.2kquestions
20kanswers
220users

How long does a GLP-1 receptor agonist stay within specification at 4 °C once reconstituted?

Asked 10 Mar 2025Modified 13 months agoViewed 17k times
20

Numbers first: a GLP-1 receptor agonist · 4 °C.

I can find plenty of assertions about this and almost no reasoning, which is usually a sign that nobody has checked.

Assume no laboratory access beyond what I can pay a third party for.

Concretely, what should I do, and how would I know afterwards whether I did it right?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
shareeditfollowflag
AF
askedayo_fadipe9.4k1610 Mar 2025
6Do you know the residual moisture? It predicts this better than any date does. – triple_agonist_q 6 months ago
add a comment

5 Answers

Sorted by votes
75

Whatever the refrigerated figure is, divide it by about 0.9. 4 °C is the condition the rule of thumb is anchored to, so it is the baseline rather than a multiplier: everything else in this thread is quoted relative to it. So a preparation with a twenty-eight day refrigerated figure has roughly 30 days at 4 °C on the same assumption — an order-of-magnitude answer, not a shelf life, and it says nothing about sterility, which has its own clock. "Within specification" also needs a specification: purity, content, or both, and at what limit. Without that the question has no numerical answer at all.

The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

At dilute concentrations, suspect adsorption before you suspect chemistry.

shareimprove this answerflag
MO
answeredmarta_okonkwo190k25818 Jun 2025
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
51

This is answerable from the chemistry rather than from anecdote, which is unusual and welcome.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

shareimprove this answerflag
ZM
answeredzainab_mustafa21k277 Jun 2025
4Adding a vote because this deserves more of them. – aine_mulcahy 4 months ago
3Adding for future readers: the domestic leg after delivery is the part you control. – Dr_Rosalind_Achebe 3 months ago
add a comment
39

Asparagine and glutamine are the deamidation risk, and methionine is the oxidation risk.

Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

Cold, dry, dark, still. Those four words cover most of the mitigation.

edited 28 Mar 2025 by leonid_marchuk — added the placebo-arm figures

shareimprove this answerflag
LM
answeredleonid_marchuk19k2713 Mar 2025
32

Stated carefully, aggregation is a physical process and is the one most often caused by handling rather than by time.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.

Sequence determines which pathways apply, so general statements are general.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

shareimprove this answerflag
C8
answeredcoldpack_8850k3729 Jun 2025
28

The short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.

Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.

Sequence decides which pathways are even available. Check the residues.

shareimprove this answerflag
HN
answeredhalvard_ness69k475 May 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.